01 July 2005 : Extended abstract from EFAS 2011
Possible induction of oral allergy syndrome during specific immunotherapy inpatients sensitive to tree pollen.
Marek Modrzyński, Edward ZawiszaMed Sci Monit 2005; 11(7): CR351-355 :: ID: 16984
Abstract
Background: Many studies have shown that specific immunotherapy may preventthe development of allergies to new allergens. Recently, however, there have been sporadic reports onthe possibility of new allergies developing during immunotherapy. The aim of this study was to evaluatethe possibility of the occurrence of food allergy and changes of sIgE concentration in patients sensitiveto tree pollen during specific immunotherapy Material/Methods: We examined 12 patients subjected to desensitizationtreatment of pollinosis caused by allergy to the pollen of Betulaceae trees, in whom only Bet v 1 sIgEwas found in serum prior to immunotherapy. The control group included 8 allergic patients who did notconsent to this treatment. Results: Bet v 2 sIgE was detected after 6 months in 3 patients (25%) andafter 18 months in another 2 patients (41.7% total). In 2 cases, oral allergy syndrome (OAS) occurredin the course of therapy. These findings were accompanied by a concomitant decrease in nasal and ocularallergic signs during the birch pollen season in the overwhelming majority of patients (91.7%). In thecontrol group, no serum occurrence of Bet v 2 sIgE was found during the 18-month observation period.Although no OAS signs appeared in any patient, the symptomatic intensity of pollinosis was not reduced.Conclusions: Due to the limitations of currently used vaccines, new allergies may be induced during immunotherapy.In sporadic cases these may be accompanied by the occurrence of specific clinical manifestations, usuallymild.
Keywords: Betula - immunology, Desensitization, Immunologic - adverse effects, Food Hypersensitivity - etiology, Food Hypersensitivity - immunology, Hypersensitivity - immunology, Hypersensitivity - therapy, Immunoglobulin E - blood, Pollen - immunology, Syndrome, Betula - immunology, Desensitization, Immunologic - adverse effects, Food Hypersensitivity - immunology, Hypersensitivity - therapy, Immunoglobulin E - blood, Pollen - immunology, Syndrome
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
14 Mar 2024 : Clinical Research
Renal Dysfunction Increases Risk of Adverse Cardiovascular Events in 5-Year Follow-Up Study of Intermediate...Med Sci Monit In Press; DOI: 10.12659/MSM.943956
15 Mar 2024 : Clinical Research
Impact of One-Lung Ventilation on Oxygenation and Ventilation Time in Thoracoscopic Heart Surgery: A Compar...Med Sci Monit In Press; DOI: 10.12659/MSM.943089
14 Mar 2024 : Clinical Research
Differential DHA and EPA Levels in Women with Preterm and Term Births: A Tertiary Hospital Study in IndonesiaMed Sci Monit In Press; DOI: 10.12659/MSM.943895
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952